Stephen Burley, M.D., Ph.D.

 

Dr. Stephen Burley currently serves as Henry Rutgers Chair and University Professor, Founding Director of the Institute for Quantitative Biomedicine, and Director of the RCSB Protein Data Bank at Rutgers, The State University of New Jersey. He also co-leads the Cancer Pharmacology Research Program at the Rutgers Cancer Institute of New Jersey. Dr. Burley is an expert in structural biology, proteomics, bioinformatics, structure/fragment-based drug discovery and clinical medicine/oncology. From 2008 to 2012, Dr. Burley was a Distinguished Lilly Research Scholar in Lilly Research Laboratories. Prior to joining Lilly, Dr. Burley co-founded Prospect Genomics, Inc., which was acquired by SGX in 2001. He then served as the Chief Scientific Officer and Senior Vice President of SGX Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Lilly in 2008. Until 2002, Burley was the Richard M. and Isabel P. Furlaud Professor at The Rockefeller University and an Investigator in the Howard Hughes Medical Institute. He has authored/coauthored more than 300 scholarly scientific articles in top peer-reviewed journals. He is a Fellow of the Royal Society of Canada, the New York Academy of Sciences, and the American Crystallographic Association.